SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as record Super Bowl betting volume is anticipated, with community discussion intensely focused on how burgeoning prediction markets, operating under different regulatory frameworks, will impact its future profitability and market share amidst its own expansion into the evolving sector ahead of its impending earnings report.

WorldFinancial

WorldFinancial (WLFI) is trending amid a U.S. House probe into a significant investment deal, fueling polarized community discussion over its legitimacy as a Trump-linked project with ambitions in stablecoins and Real World Asset tokenization.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as the community hotly debates the implications of the company's abrupt halt of its compounded weight-loss pill due to intense regulatory scrutiny, with bulls anticipating a short squeeze now that legal overhang is removed and bears expressing deep concern over management's decision-making and potential impact on growth.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors await its upcoming earnings report and the highly anticipated, yet debated, POSCO partnership, with community sentiment split between expectations of a significant upside from strong HRC prices and the termination of a costly slab contract, versus concerns over recent equity dilution and historical underperformance within the steel sector.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is buzzing after hitting a $1 trillion market cap and joining the Nasdaq-100, with its strategic AI partnerships and expanding e-commerce driving a narrative of robust, tech-driven retail transformation that has the community actively discussing its surprising strength.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors eagerly await its BLA resubmission in February, a key step validated by the FDA's request for the full HOPE-3 clinical study report without additional trials. This development reinforces confidence in its Duchenne muscular dystrophy therapy and promising exosome platform amidst discussions of institutional interest.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending due to significant Super Bowl exposure for its Briumvi MS treatment, featuring Christina Applegate, a campaign that the community views as a "huge win" for raising awareness and highlighting the drug's best-in-class efficacy amid concerns over competitors like Roche's Fenebrutinib. The widespread discussion emphasizes Briumvi's strong safety profile and potential to attract new patients, fueling optimism for its market position.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is trending after the FDA accepted its New Drug Application for CTx-1301 and set a May 2026 PDUFA date for its innovative once-daily ADHD treatment. The community is actively discussing the stock's low market cap and tiny float, anticipating potential US patent news and significant upside, including possible buyouts.

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton Dickinson & Co.

Becton, Dickinson And Co.

Becton Dickinson is trending as investors anticipate its Q1 earnings, with community discussions weighing expected declines against broad product demand and significant corporate actions like the pending Waters Corp. spin-off. Recent innovations in AI-driven flow cytometry, expanded biologics partnerships, and new medical device approvals are also driving conversation around the stock's current valuation and future growth.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is gaining significant attention due to its critical role in cutting-edge defense contracts for AR systems like Anduril's EagleEye and surging demand for its space and AI infrastructure optics, with community discussion highlighting its exceptionally tight float and strong insider ownership as key bullish factors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Editas Medicine (NASDAQ:EDIT) Share Price Crosses Below 50 Day Moving Average - Here's What Happened

Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50 Day Moving Average - What's Next...

Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50 Day Moving Average - What's Next?

Editas Medicine (NASDAQ:EDIT) Share Price Passes Below 50-Day Moving Average - What's Next...

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat.com...

Cathie Wood shells out $1.3 million on biotech stock

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics (NTLA), scooping up 145,153 shares in the gene-editing play. For the most part, it...

Editas Medicine (NASDAQ:EDIT) Stock Price Down 2.9% - Should You Sell?

Editas Medicine (NASDAQ:EDIT) Shares Down 2.9% - Should You Sell...

Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts

Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has been given an average rating of "Hold" by the twelve ratings firms that are currently covering the company, Marketbeat reports. Two equities...

Editas Medicine (NASDAQ:EDIT) CEO Sells $12,046.45 in Stock

Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,603 shares of the business's stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold...

Insider Selling: Editas Medicine (NASDAQ:EDIT) CEO Sells 5,603 Shares of Stock

Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,603 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of...

Editas Medicine (NASDAQ:EDIT) Shares Cross Below 50-Day Moving Average - Time to Sell?

Editas Medicine (NASDAQ:EDIT) Shares Cross Below Fifty Day Moving Average - Should You Sell...

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Editas Medicine Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

EDIT
Editas Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EDIT News

EDITEditas Medicine Inc